Shutterstock.com
Despite medical treatment, many people with type 2 diabetes have ongoing obesity and poorly controlled blood glucose.
A team from City Hospital Birmingham explored the feasibility of using a device called an Endobarrier, which sits inside the small intestine to prevent food absorption, in the NHS.
153 people with uncontrolled type 2 diabetes and obesity were referred to the service, 65 were accepted and 50 had the 60cm device endoscopically implanted.
The researchers found improvements in HbA1c levels, weight loss, daily insulin dose and reduced liver fat, which were sustained in 65% of patients six months after device removal. Patient satisfaction was also high, many reported improvements in wellbeing, energy and exercise ability and 94% said they would recommend the service to others.
Presenting their findings at the European Association for the Study of Diabetes Annual Meeting (11–15 September 2017), the team said, with its acceptable safety profile and effectiveness, the Endobarrier service could be integrated into existing endoscopy units to be delivered throughout the NHS[1]
.
References
[1] Ryder R, Yadagiri M, Irwin S et al. Efficacy, safety, tolerability and sustainability outcomes of endoscopic proximal intestinal exclusion with EndoBarrier: 1st UK NHS EndoBarrier service for diabesity. Presented at: European Association for the Study of Diabetes (EASD) Annual Meeting; 11–15 September 2017; Lisbon, Portugal. Abstract available at: https://www.easd.org/myeasd/home.html#!resources/efficacy-safety-tolerability-and-sustainability-outcomes-of-endoscopic-proximal-intestinal-exclusion-with-endobarrier-1st-uk-nhs-endobarrier-service-for-diabesity (accessed October 2017)
You may also be interested in
Manufacturer confirms discontinuation of type 2 diabetes mellitus treatment Victoza
Pharmacy-led national diabetes screening service could save NHS £50m a year, says CCA
